权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Characterizing and engineering toluene o-xylene monooxygenase for the synthesis of common drug metabolites

用于合成常见药物代谢物的甲苯邻二甲苯单加氧酶的表征和工程设计

基本信息

批准号：
10674949
负责人：
Gonul Schara
金额：
$ 10.73万
依托单位：
CALIFORNIA STATE UNIVERSITY-STANISLAUS
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-04 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10674949
关键词：
Active Sites Agar Aniline Area Biological Assay Bioremediations Bupropion Catalysis Cells Chemistry Clinical Research Codon Nucleotides Color Cytochrome P450 Development Disadvantaged Disease Docking Drug Kinetics Engineering Ensure Enzymes Escherichia coli Family Friends Funding Generations Goals Grant Health High Pressure Liquid Chromatography Human In Vitro Investigation Investigational New Drug Application Libraries Light Liver Membrane Mixed Function Oxygenases Modeling Motivation Mutagenesis NADH Nuclear Magnetic Resonance Nylons Omeprazole Oxygenases Pathway interactions Performance Pharmaceutical Preparations Pharmacologic Substance Phase Plasmids Positioning Attribute Preclinical Drug Development Preparation Probability Process Production Property Protein Engineering Pseudomonas Research Research Project Grants Research Proposals Role Science Site-Directed Mutagenesis Specificity Spottings Structure Structure-Activity Relationship Students Study models Substrate Specificity Techniques Ticlopidine Time Toxic effect Toxicity Tests Toxicology Underrepresented Populations United States Food and Drug Administration United States National Institutes of Health Variant career career development catalyst chemical synthesis cofactor computerized tools cost drug biological activity drug development drug synthesis drug-like compound enzyme activity experience experimental study exposed human population improved in vivo interest liquid chromatography mass spectroscopy new chemical entity oxidation pre-clinical preclinical study programs research and development scale up simulation success toluene 2-xylene monooxygenase

项目摘要

Project Summary/Abstract As drugs are metabolized in the body, their metabolites represent new chemical entities to which humans are exposed. Thus, investigating the toxicities and characterizing biological activities of drug metabolites is crucial for the development of safe, effective drugs. In fact, pharmacokinetic studies are critical components of investigational new drug applications to the US Food and Drug Administration. As a part of these studies, however, large quantities of pure metabolites are needed to characterize them in vitro and, especially in vivo. The chemical synthesis of drug metabolites is problematic in terms of yield, selectivity, and can be a major cost- driver in preclinical studies. Direct enzymatic synthesis of drug metabolites is an attractive alternative. Although P450 monooxygenase enzymes, found in human liver, have been in the spot light as drug metabolizing biocatalysts, many challenges still remain such as low biocatalytic activity, limited drug substrate specificity and product range. The investigation of alternate enzymes or biocatalysts may lead to a diversified metabolites product spectra and open up new horizons for efficient metabolite production. Due to its excellent chemistry, wide substrate range, and malleable catalytic activity, we propose to investigate the biocatalyst toluene o-xylene monooxygenase (ToMO) of Pseudomonas sp. OX1 as a drug metabolizing enzyme. Using protein engineering techniques, we plan to create ToMO variants with enhanced drug oxidation activity and fine-tuned specificity. Using protein engineering, we previously created several variants of ToMO for green chemistry and bioremediation applications. The prospect of using ToMO and its engineered variants for the synthesis of drug metabolites presents a new and exciting approach. Our long-term goal is to improve the versatility of ToMO even further by exploring and expanding its substrate repertoire for drug development and pharmaceutical production. The specific aims of this project are to characterize wild-type ToMO for drug oxidation activity with 6 different drug substrates and drug-like candidates including aniline, acetanilide, bupropion, ticlopidine, chlorphenamine, and omeprazole (Aim 1), construct ToMO variant libraries using protein engineering and screen for further improvements (Aim 2), and sequence, model, and characterize positive ToMO variants for drug oxidation activity (Aim 3).

项目总结/文摘